185 related articles for article (PubMed ID: 35219151)
21. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria.
Rengarajan J; Sassetti CM; Naroditskaya V; Sloutsky A; Bloom BR; Rubin EJ
Mol Microbiol; 2004 Jul; 53(1):275-82. PubMed ID: 15225321
[TBL] [Abstract][Full Text] [Related]
22. Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis.
Zhao F; Wang XD; Erber LN; Luo M; Guo AZ; Yang SS; Gu J; Turman BJ; Gao YR; Li DF; Cui ZQ; Zhang ZP; Bi LJ; Baughn AD; Zhang XE; Deng JY
Antimicrob Agents Chemother; 2014; 58(3):1479-87. PubMed ID: 24366731
[TBL] [Abstract][Full Text] [Related]
23. Para-aminosalicylic acid: the return of an old friend.
Donald PR; Diacon AH
Lancet Infect Dis; 2015 Sep; 15(9):1091-1099. PubMed ID: 26277036
[TBL] [Abstract][Full Text] [Related]
24. French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPAS(®) in MDR-TB patients.
Kibleur Y; Veziris N
Chemotherapy; 2014; 60(3):174-9. PubMed ID: 25823752
[TBL] [Abstract][Full Text] [Related]
25. Cross-resistance of isoniazid, para-aminosalicylic acid and pasiniazid against isoniazid-resistant Mycobacterium tuberculosis isolates in China.
Li G; Zhang J; Jiang Y; Zhao LL; Liu H; Li M; Zhao X; Wan K
J Glob Antimicrob Resist; 2020 Mar; 20():275-281. PubMed ID: 31425771
[TBL] [Abstract][Full Text] [Related]
26. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.
Gupta D; Varghese Gupta S; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
Mol Pharm; 2013 Feb; 10(2):512-22. PubMed ID: 23244438
[TBL] [Abstract][Full Text] [Related]
27. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.
Adeniji AA; Knoll KE; Loots DT
Appl Microbiol Biotechnol; 2020 Jul; 104(13):5633-5662. PubMed ID: 32372202
[TBL] [Abstract][Full Text] [Related]
28. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
[TBL] [Abstract][Full Text] [Related]
29. Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance.
Feuerriegel S; Köser C; Trübe L; Archer J; Rüsch Gerdes S; Richter E; Niemann S
Antimicrob Agents Chemother; 2010 Nov; 54(11):4794-8. PubMed ID: 20805400
[TBL] [Abstract][Full Text] [Related]
30. Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: an update.
Chaiprasert A; Srimuang S; Tingtoy N; Makhao N; Sirirudeeporn P; Tomnongdee N; Theankeaw O; Charoensook S; Leechawengwongs M; Prammananan T
Int J Tuberc Lung Dis; 2014 Aug; 18(8):961-3. PubMed ID: 25199012
[TBL] [Abstract][Full Text] [Related]
31. [Mutations in the thymidylate synthase gene is a major mechanism in the para-aminosalicylic acid resistance of M. tuberculosis].
Zhang ZD; Zhao YL; Li ZH; Jia HY; Liu YH; Chen X; Liu ZQ; Du BP; Xing AY; Ma Y
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Sep; 30(9):683-5. PubMed ID: 18070553
[TBL] [Abstract][Full Text] [Related]
32. Decreased Methylenetetrahydrofolate Reductase Activity Leads to Increased Sensitivity to
Yu JF; Xu JT; Yang SS; Gao MN; Si HR; Xiong DY; Gu J; Wu ZL; Zhou J; Deng JY
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0146521. PubMed ID: 34780266
[TBL] [Abstract][Full Text] [Related]
33. PAS infusion in treatment of multidrug-resistant tuberculosis.
Fodor T; Pataki G; Schrettner M
Int J Tuberc Lung Dis; 2000 Feb; 4(2):187-8. PubMed ID: 10694102
[No Abstract] [Full Text] [Related]
34. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
Starrett JE; Tortolani DR; Russell J; Hitchcock MJ; Whiterock V; Martin JC; Mansuri MM
J Med Chem; 1994 Jun; 37(12):1857-64. PubMed ID: 8021925
[TBL] [Abstract][Full Text] [Related]
35. Hybridization Approach Toward Novel Antituberculars: Design, Synthesis, and Biological Evaluation of Compounds Combining Pyrazinamide and 4-Aminosalicylic Acid.
Bouz G; Šlechta P; Jand'ourek O; Konečná K; Paterová P; Bárta P; Novák M; Kučera R; Dal NK; Fenaroli F; Zemanová J; Forbak M; Korduláková J; Pavliš O; Kubíčková P; Doležal M; Zitko J
ACS Infect Dis; 2023 Jan; 9(1):79-96. PubMed ID: 36577009
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of
Parvez MM; Shin HJ; Jung JA; Shin JG
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223391
[No Abstract] [Full Text] [Related]
37. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
38. [Clinical analysis of protionamide and para-aminosalicylic acid induced hepatotoxicity in 129 cases].
Ge QP; Wang QF; Duan HF; Wang J; Chu NH
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Oct; 36(10):737-40. PubMed ID: 24433800
[TBL] [Abstract][Full Text] [Related]
39. A five-year review of prevalence and treatment outcomes of pre-extensively drug-resistant plus additional drug-resistant tuberculosis in the Henan Provincial Tuberculosis Clinical Medicine Research Centre.
Li Z; Liu F; Chen H; Han Y; You Y; Xie Y; Zhao Y; Tan J; Guo X; Cheng Y; Wang Y; Li J; Cheng M; Xia S; Niu X; Wei L; Wang W
J Glob Antimicrob Resist; 2022 Dec; 31():328-336. PubMed ID: 36210030
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
Prasad R; Verma SK; Sahai S; Kumar S; Jain A
Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
